Side-by-side comparison of AI visibility scores, market position, and capabilities
Women's health medtech with $3.9B FY2024 revenue; 3D Genius Mammography market leader; Panther molecular diagnostics platform; annual screening guidelines expand mammography TAM by ~30%.
Hologic is a global medical technology company uniquely dedicated to women's health, founded in 1985 and headquartered in Marlborough, Massachusetts, trading on Nasdaq (HOLX). The company generated approximately $3.9 billion in revenues for fiscal year 2024 (ending September 28) under CEO Stephen MacMillan, who has led Hologic since 2013 and transformed it from a single-product mammography company into a diversified women's health platform. Hologic's four business segments serve distinct clinical needs: Diagnostics (Panther molecular testing platform, cervical health testing, and COVID-19 diagnostics), Breast Health (3D mammography, breast biopsy guidance systems, radiation therapy), Surgical (NovaSure endometrial ablation, MyoSure fibroid removal, and minimally invasive hysteroscopy), and Skeletal Health (bone density measurement).
Franklin Lakes NJ medical technology (NYSE: BDX) at $21.8B FY2025 revenue (+8.2%); $17.5B Reverse Morris Trust spinoff with Waters (2025), Edwards critical care acquisition $4.2B (2024) competing with Baxter for infusion systems.
Becton, Dickinson and Company (BD) is a Franklin Lakes, New Jersey-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BDX) as an S&P 500 Health Care component — manufacturing and selling medical supplies, devices, laboratory equipment, and diagnostic products through approximately 74,000 employees serving healthcare institutions, clinical laboratories, pharmaceutical companies, and life science researchers in over 190 countries. In fiscal year 2025 (ended September 30, 2025), BD reported full-year revenue of $21.8 billion (up 8.2% year-over-year) with Q4 FY2025 revenue of $5.9 billion (+8.3% reported, +3.9% organic growth), and declared a quarterly dividend of $1.05 per share (+1%). Founded in 1897 in New York City by Maxwell Becton and Fairleigh Dickinson Sr. as a thermometer and surgical instrument maker, BD has grown through 125+ years of acquisitions to become a Fortune 500 ($21.8B revenue, #211 on 2024 Fortune 500) global medtech leader. The company operates through three segments: BD Medical (~50% of revenue, IV catheters, syringes, prefillable drug delivery systems, and medication management solutions), BD Life Sciences (flow cytometry, microbiology, molecular diagnostics, and lab automation), and BD Interventional (advanced patient monitoring, interventional cardiology, and peripheral vascular interventions). BD invests $1.2+ billion annually in R&D. In 2024, BD acquired Edwards Lifesciences' critical care monitoring unit for $4.2 billion.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.